
Eisai has criticised NICE for being too narrow minded on assessing new drugs, and has warned it may pull its …

Eisai is expanding its UK headquarters to support the company’s growing European, Middle Eastern and African business. The expansion will …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

